The efficacy and tolerability of direct-acting antivirals (DAAs) therapy for HCV infection in kidney transplant recipients are unclear. In this meta-analysis including 24 studies with 892 kidney transplant recipients, we demonstrate excellent efficacy and tolerability profiles with estimated SVR12 rate of 97% and estimated rate of discontinuation of DAAs of 2%.
Introduction
Hepatitis C virus (HCV) infection universally affects greater than 200 million people worldwide (1) . Transmission of HCV occurs essentially via blood transfusion. Consequently, the prevalences of HCV infection in end-state kidney disease on hemodialysis (2.6%-22.9% in Western countries) and in kidney transplant recipients (1.8%-8% in developed countries) are higher than in the general population (~1% in the United States) (2) (3) (4) (5) . Most kidney transplant patients have received HCV infection while on dialysis. Transmission from organ transplantation is a scarcity in this current era due to decent donor screening (6) . In the current years, remarkable advancement has been made in the development of oral anti-HCV agents that undeviatingly inhibit and target multiple HCV viral proteins with interferon (IFN) free direct-acting antiviral (DAA) therapies with excellent reported sustained
Inclusion criteria and outcomes
The inclusion criteria were 1) observational studies or randomized controlled trials (RCTs) published as original studies or conference abstracts that evaluated the efficacy and safety of DAAs for treatment of HCV infection in kidney transplant populations and 2) crude number of kidney transplant patients who achieved SVR or developed adverse effects with DAA therapy were provided. Our outcomes of interest in this study included the efficacy of DAA treatment representing by pooled rate of SVR and serious adverse side effects requiring DAA discontinuation representing by pooled rate of DAA discontinuation.
Data extraction
A structured data collection report utilized to derive the data from included studies consisted of the first author, country where studies were conducted, type of study, year of publication, total number of kidney transplant patients, HCV genotype, baseline estimated glomerular filtration rate (eGFR) (mL/min/BSA), DAA regimens, time between transplant to DAA treatment, duration of DAA treatment, SVR12, reported adverse events and drug-related serious adverse events, adverse event details, change in renal function with DAA treatment, changes in immunosuppression (dose changes during DAA treatment), rate of treatment discontinuation due to serious adverse events. 
Statistical analysis
MetaXL software (EpiGear International Pty Ltd) (13) was used for meta-analysis of efficacy and safety of DAA treatment. A random-effect model was employed rather than a fixed-effect model, given the high likelihood of between-study variances. Statistical heterogeneity was appraised using Cochran's Q test. This statistic was complemented with the I 2 statistic, which quantifies the proportion of the total variation crossed studies that is due to heterogeneity rather than chance. An I 2 of 0%-25% renders insignificant heterogeneity, 26%-50% low heterogeneity, 51%-75% moderate heterogeneity and >75% high heterogeneity (14) . The likelihood of publication bias was evaluated by funnel plots of the logarithm of odds ratios vs. their standard errors (15) .
Results
The search strategy yielded 643 potentially relevant articles: 540 were excluded based on the title and abstract which apparently showed that they did not fulfill inclusion criteria regarding study design, article type, population, or outcome of interest ( Figure 1 ). The remaining 103 articles underwent full-length review, with 79 excluded because they were not observational studies or RCTs (n = 10) or did not report outcomes of interest (n = 69). Twentyfour studies (1, 10, 11, with 892 kidney transplant recipients were included in the meta-analysis. Table 1 and  Table 2 contain individual characteristics of all included studies. 
Goyal et al (18)
One patient had AKI secondary to CyA toxicity No other major adverse effects.
No rejection
Mean serum creatinine remained unchanged (P = 0.5) 
Gallegos-Orozco et al (21)
Very well tolerated with (2/6) severe adverse events in two of three patients on ribavirin (severe anemia requiring blood transfusions and ribavirin dose reduction)
The most frequent adverse events included fatigue (n = 3), headache (n = 2), anemia requiring blood transfusion and erythropoietin injections (n = 2), and nausea (n = 1). Both patients who developed severe anemia (hemoglobin < 8 g/dl) was on ribavirin.
N/A
All of the patients have functioning grafts at six months to one-year post-renal transplant.
N/A 0/6 (0%) N/A Hussein et al (22) Well tolerated. No major adverse events. Two patients required blood transfusion and temporary RBV dose reduction due to anemia 12 weeks after the initiation of treatment.
Renal function was stable throughout the treatment course and there were no episodes of acute rejection while on treatment.
El-Halawany et al (23)
One patient had anemia related to RBV and required dose adjustment with resolution of his anemia.
There were no episodes of graft rejection and none required modification in immunosuppression.
All KT recipients had either stable or improved creatinine during treatment of their HCV.
Grade 2 or 3 anemia appeared in 14 (33%) RBV and 9 (15%) without RBV Others adverse events reported were grade 2 and grade 3 hyperbilirubinemia in 4 (4%) and 2 (2%) patients, respectively (all but one in patients taking RBV).
There were 3 episodes of acute humoral graft
No statistically significant differences in the mean level of serum creatinine, eGFR and proteinuria before and after treatment. 17 (16%) patients experienced renal dysfunction (increase in serum creatinine > 25%) during antiviral therapy, of whom 65% were cirrhotic in comparison with only 29% cirrhotic patients who did not develop significant renal dysfunction (P =0.004) 57 (55%) patients required immunosuppression dose adjustment. Tacrolimus doses required adjustments in 47 of the 75 (62.6 %) patients: tacrolimus dose was increased in 34 of 47 and reduced in 13 of 47. This was not significantly associated with a particular regimen of DAAs (P > 0.05). Cyclosporine doses required adjustments in 7 of the 14 patients (50%) receiving a cyclosporine-based therapy (dose reduction in all). Only 6 patients were under everolimus treatment and doses were increased in 2 of them.
0%
A non-negligible number of patients, most of them cirrhotic, developed mild allograft dysfunction and a significant proportion of patients required immunosuppression dose adjustment, warranting a close follow-up during therapy.
Kirushnan et al (25)
The drugs were well tolerated in the majority. 1 patient required erythropoietin temporarily after RBV therapy.
There were no new onset graft dysfunctions indicating no major drug interactions between SOF and immunosuppressants predisposing either to rejection or calcineurin toxicity.
There was no change in the baseline creatinine 2 weeks and 1 month after initiation of therapy. 
No significant change in renal function
2 patients had a decrease in tacrolimus levels to less than 4 ng/mL that improved with appropriate adjustment by the treating physician.
(1 treated with SOF+ LDV+RBV and 1 treated with SOF+ RBV.)
0%
Patients with proteinuria or lower GFR should be monitored more closely.
Patients with more than 300 mg/g of proteinuria were significantly more likely to develop worsening proteinuria than those with less than 300 mg/g of proteinuria at the start of therapy (P<0.001). None of the patients with minimal proteinuria had significant changes in proteinuria or serum creatinine levels with therapy. (4/6 had kidney biopsies during or after completion of therapy. Results of these biopsies were variable and included non-specific glomerular changes in 2 cases, diabetic nephropathy in 1 case and moderate IFTA in the fourth case).
There was no significant change in Panel Reactive Antibody (PRA) class I or class II post therapy (P=0.45 and P=0.13 respectively).
Martin et al (32)
None of the 21 patients had severe adverse events and none died during treatment.
N/A
The average change in SCr was + 16% (SD = 0.67).
Immunosuppression dosage did not change for 15(71%) patients, it was increased for 2 patients, decreased for 3 patients, and changed in both directions for 1 patient.
0% N/A
Aull et al (33) Adverse events included anemia requiring RBV dose reduction or discontinuation (n=2), headache (n=2), acute kidney injury due to tacrolimus toxicity, diarrhea, & worsening blood glucose control (n=1 each).
One patient died 4 months after achieving SVR of an unknown cause.
The first patient selfdiscontinued it due to high blood pressure and numbness in his mouth. The second had anemia and resulting weakness from the ribavirin and discontinued it on his own. N/A There were no episodes of acute rejection or other relevant adverse events.
N/A
There were no significant differences in Tac (p= 0.911) or MMF levels (p= 0.785) between baseline and EOT. Tac doses had to be increased in 92.8% (13/14) of patients by a median of 66.0%.
The treatment was well tolerated, with no episodes of adverse events while on therapy or relevant adverse events.
No episodes of AR while on therapy
There were no differences between baseline and EOT (20 patients) in graft function (50. There were no episodes of graft rejection and none required modification in immunosuppression.
All KT recipients had stable renal and liver function during and after the completion of therapy N/A 0% N/A Kogiso et al (41) One case was dropped out due to mild fever and renal impairment. N/A
The other cases showed no severe adverse events in liver or renal function.
The tacrolimus concentration was maintained and no substantial dose adjustment was required. 
Efficacy of DAAs for treatment of HCV-infected kidney transplant recipients
Of 24 studies, 22 were included in the analysis to assess the effectiveness of DAA treatment for HCV infection among kidney transplant recipients as shown in Table 1 . Details regarding HCV genotype, baseline eGFR, DAA regimens, time between transplants to DAA treatment, duration of DAA treatment of each included study were provided in Table 1 . The estimated SVR12 rate with DAAs treatment for HCV among kidney transplant patients was 97% (95% CI: 95%-99%; I 2 = 22%), as demonstrated in Figure 2 .
Safety of DAAs for treatment of HCV-infected kidney transplant recipients
Of 24 studies, 23 were included in the analysis to assess the safety of DAA treatment for HCV infection among kidney transplant recipients as shown in Table 2 . Reported adverse events and drug-related serious adverse events, adverse event details, change in renal function with DAA treatment, changes in immunosuppression, rate of treatment discontinuation due to serious adverse events of each included study were provided in Table 2 . Reported treatment-related serious adverse events included bradycardia with syncope especially co-administration of sofosbuvir (SOF) with amiodarone (1,10), pulmonary embolism (10), gastrointestinal bleeding (1), portal vein thrombosis (1), bacteremia (1), anemia especially with regimens including RBV, and uncommonly increased serum creatinine (10, 18) . The estimated rate of discontinuation of DAAs treatment for HCV among kidney transplant patients was 2% (95%CI: 1%-3%; I 2 = 0%), as demonstrated in Figure 3 .
Evaluation for publication bias
Funnel plots to appraise publication bias regarding the efficacy and safety of DAA treatment in recipients with DAA treatment for HCV infection are presented in Figure  S1 -S2. Overall, the publication bias was insignificant.
Discussion
In this meta-analysis of 892 kidney transplant recipients, we showed an excellent efficacy of DAA therapy for treatment of HCV infection among kidney transplant recipients with overall estimated SVR12 rate of HCV after DAA therapy in kidney transplant recipients of 97%. Besides, DAA therapy in kidney transplant recipients is well-tolerated with an overall estimated discontinuation rate of 2%. Before the development of DAA therapy, the use of IFNbased treatment for HCV infection has been restricted to pretransplant administration due to concerns related to acute allograft injury, immune stimulation related allograft rejection, allograft loss, and poor tolerability (1, 9) . Also, IFN-based regimens have unfortunately been limited in efficacy and poorly tolerated in the end stage renal disease patients (9) . Recently, Studies have demonstrated that novel DAA-based antiviral therapies are efficient for HCV patients with stage 4-5 chronic kidney disease with SVR as high as 89% to 94.3% (8, 42, 43) . In this current study, we demonstrated an excellent efficacy of the use of DAAs in post-kidney transplantation setting with pooled estimated SVR12 of 97%. Despite favorable safety and tolerability profile of DAAs treatment for HCV among kidney transplant patients with only 2% rate of discontinuation of treatment, there are several cautions of DAA therapy and drug-drug interactions bear mention. One of the major reported serious adverse effects was bradycardia with syncope (1, 10) . Amiodarone is a known inhibitor of P-GP transport, and SOF is partially cleared via the P-GP system (44) . A decreased in P-GP activity means patients taking amiodarone could be exposed to higher levels of SOF, which is thought to be the cause of bradycardia. Thus, excellent communication between patients and physicians with transplant center are very important to avoid potential drug-drug interactions (10) . In addition, drugdrug interactions between DAA and immunosuppression need to be carefully considered. Calcineurin inhibitor (CNI) levels have been shown to fluctuate during and even after DAA treatment is completed (1, 10, 11, .
Conclusion
In summary, our meta-analysis shows excellent efficacy and tolerability profiles of DAA therapy for HCV-infected kidney transplant recipients. HCV infection should no longer be a major concern among kidney transplant recipients.
Limitations of the study
There are several limitations of our meta-analysis. First, almost all included studies were observational studies with various DAA regimens. Thus, we can only demonstrate an overall efficacy and tolerability of DAA therapy for HCV infection among kidney transplant recipients. Recently, Colombo et al (10) conducted a multicenter RCT evaluating efficacy and safety of the combination of SOF and LDV in kidney transplant recipients for total of 12 weeks or 24 weeks of treatment. They found this SOF and LDV combination effective and well tolerated among patients with kidney transplantation (Table 1) . Second, the majority of patients in the included studies had HCV genotype I, leading to limiting the generalizability of the results to other HCV genotypes. Finally, HCV-infected kidney transplant recipients in most included studies received DAA therapy later than 3 to 6 months posttransplantation. The data on the efficacy and safety of DAA therapy during immediate post-kidney transplant, however, were lacking in the included studies in our metaanalysis.
